Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy
- Author:
Yunjeong JANG
1
;
Eun Yoon CHO
;
Soo Youn CHO
Author Information
- Publication Type:Case Report
- Keywords: Breast neoplasms; Receptor, ErbB-2; Adenocarcinoma, mucinous; Neoadjuvant therapy; Carcinoma, signet ring cell
- MeSH: Adenocarcinoma, Mucinous; Breast Neoplasms; Carcinoma, Signet Ring Cell; Cell Differentiation; Drug Therapy; Epidermal Growth Factor; Estrogens; Humans; Mucins; Neoadjuvant Therapy; Polymerase Chain Reaction; Population Characteristics; Receptor, Epidermal Growth Factor; Receptor, ErbB-2; Trastuzumab
- From:Journal of Breast Cancer 2019;22(2):336-340
- CountryRepublic of Korea
- Language:English
- Abstract: Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) negative. Here, we present a case of HER2-positive MC with an unusual signet ring cell differentiation. It is very rare that a breast tumor consists entirely of signet ring cells. The tumor showed pathologic complete response (pCR) after neoadjuvant chemotherapy with trastuzumab and pertuzumab. pCR of HER2-positive MC has rarely been described in literature. It is important to consider the biological heterogeneity of MCs for effective management.
